16.02.2020, 1820 Zeichen
Another good week for our ATX with more than 2 per cent up. News came from Andritz, ams, A1 Telekom Austria, Strabag, Bawag, Rosenbauer, VIG, Wolftank-Adisa, Kapsch TrafficCom and Zumtobel.
BSNgine weekly Spitout: The ATX up 2,08% to 3.212,48 points this week. Year-to-date the ATX is now at 0,8%. Up to now there were 15 days with a positive and 17 with a negative gain. From the year-high we are 0,52% away, from the low 5,1%. Statistically the best weekday so far 2020 is Tuesday with 0,42%, the weakest is Monday with -0,59%.
These are the best-performers this week: Uniqa 12,25% in front of DO&CO 7,8% and Polytec 7,47%. And the following stocks performed worst: Kapsch TrafficCom -3,82% in front of Zumtobel -2,78% and Rosenbauer -2,28%.
Further highlights this week: Bawag for 9 days in a row up (13,19% gain from 38,52 to 43,6), also CA Immo 7 days up (5,95% gain from 39,5 to 41,85), DO&CO 5 days up (7,8% gain from 89,7 to 96,7), Immofinanz 4 days up (4,34% gain from 25,35 to 26,45), Telekom Austria 4 days up (2,18% gain from 7,34 to 7,5), RBI 4 days up (2,64% gain from 21,95 to 22,53), Addiko Bank 3 days up (1,76% gain from 14,74 to 15), S Immo 3 days up (1,74% gain from 25,9 to 26,35).
Best-performers year-to-date as of now: Semperit 19,93% (last year: 11,85 percent) followed by S Immo 18,16% (last year: 53,37 percent) and DO&CO 12,57% (last year: 6,31 percent). And the worst-performing stocks year-to-date: Lenzing -15,4% (Vorjahr: 4,22 percent), followed by SBO -15,11% (Vorjahr: -12,29 percent) and Kapsch TrafficCom -12,2% (Vorjahr: -13,68 percent).
High above the MA200: S Immo 25,1%, CA Immo 21,93% and Wienerberger 21,8%.
Down under the MA200: SBO -28,09%, Lenzing -21,48% and Kapsch TrafficCom -17,97%.
(From the 21st Austria weekly https://www.boerse-social.com/21staustria (15/02/2020)
Börsenradio Live-Blick, Do. 28.3.24: Heute März-Ultimo, geht sich DAX 18500 aus? Schönes bei Zalando, AT&S und Gold. Frohe Ostern!
Evotec
Evotec ist ein Wirkstoffforschungs- und -entwicklungsunternehmen, das in Forschungsallianzen und Entwicklungspartnerschaften mit Pharma- und Biotechnologieunternehmen, akademischen Einrichtungen, Patientenorganisationen und Risikokapitalgesellschaften Ansätze zur Entwicklung neuer pharmazeutischer Produkte vorantreibt.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner